Dean Investment Associates LLC trimmed its holdings in shares of C R Bard Inc (NYSE:BCR) by 29.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,963 shares of the medical instruments supplier’s stock after selling 803 shares during the quarter. Dean Investment Associates LLC’s holdings in C R Bard were worth $650,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Monroe Bank & Trust MI lifted its position in shares of C R Bard by 65.6% during the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock worth $100,000 after purchasing an additional 177 shares during the last quarter. Patten Group Inc. lifted its position in shares of C R Bard by 66.0% during the third quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 221 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in shares of C R Bard during the third quarter worth $170,000. Fieldpoint Private Securities LLC bought a new stake in shares of C R Bard during the third quarter worth $234,000. Finally, First National Trust Co. lifted its position in shares of C R Bard by 48.1% during the third quarter. First National Trust Co. now owns 985 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 320 shares during the last quarter. Institutional investors and hedge funds own 79.11% of the company’s stock.
In other news, insider Jim C. Beasley sold 15,044 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $332.00, for a total transaction of $4,994,608.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jim C. Beasley sold 3,395 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $332.00, for a total value of $1,127,140.00. Following the transaction, the insider now owns 25,630 shares in the company, valued at approximately $8,509,160. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,546 shares of company stock worth $10,826,150. Insiders own 0.80% of the company’s stock.
Several analysts have recently weighed in on BCR shares. Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research report on Tuesday, December 26th. Barclays lifted their target price on C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Cowen restated a “hold” rating and set a $317.00 price target on shares of C R Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. C R Bard currently has a consensus rating of “Hold” and an average price target of $320.83.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/02/09/c-r-bard-inc-bcr-shares-sold-by-dean-investment-associates-llc.html.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.